Rosen Law Firm Announces Deadline for Ultragenyx Pharmaceutical Investors

The firm is encouraging shareholders to take action before the final deadline.

Mar. 30, 2026 at 9:28pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a carefully arranged composition of premium, polished objects such as a metal briefcase, a glass paperweight, and a sleek fountain pen, all set against a clean, monochromatic background, conceptually representing the legal and financial aspects of the Ultragenyx Pharmaceutical case.The Rosen Law Firm's investigation into Ultragenyx Pharmaceutical raises questions about the company's financial transparency and accountability.NYC Today

The Rosen Law Firm, a highly recognized law firm, is urging investors who purchased Ultragenyx Pharmaceutical securities to take action before the final deadline. The firm is investigating potential securities claims on behalf of Ultragenyx shareholders and is encouraging those affected to contact the firm to discuss their options.

Why it matters

This announcement from the Rosen Law Firm indicates that there may be legal issues or concerns surrounding Ultragenyx Pharmaceutical that could impact its shareholders. Investors will want to carefully consider their options before the final deadline passes.

The details

The Rosen Law Firm is investigating potential securities claims on behalf of Ultragenyx Pharmaceutical shareholders. The firm is encouraging those who purchased Ultragenyx securities to contact them to discuss their options before the final deadline.

  • The final deadline for Ultragenyx Pharmaceutical investors to take action is approaching.

The players

Rosen Law Firm

A highly recognized law firm that is investigating potential securities claims on behalf of Ultragenyx Pharmaceutical shareholders.

Ultragenyx Pharmaceutical

A biopharmaceutical company that develops and commercializes novel products for the treatment of rare and ultra-rare genetic diseases.

Got photos? Submit your photos here. ›

What’s next

Ultragenyx Pharmaceutical investors have until the final deadline to contact the Rosen Law Firm to discuss their options.

The takeaway

This announcement from the Rosen Law Firm suggests that there may be legal issues or concerns surrounding Ultragenyx Pharmaceutical that could impact its shareholders, and investors will want to carefully consider their options before the final deadline passes.